Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. Centre Jean Perrin, Clermont-Ferrand, France

Survival: 11.1 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Paraplatin
Country: France
City/State/Province: Clermont-Ferrand
Hospital: Centre Jean Perrin
Journal: Link
Date: 2/2006

Patients: This Phase II study involved 40 men with metastatic hormone-refractory prostate cancer. None of the patients had chemotherapy before the study. The patients were randomized into two groups. Group B had 20 men with a median age of 64 years (at diagnosis).

Treatment: For Group B, treatment consisted of one chemotherapeutic agent: mitoxantrone. All patients received supplemental prednisone.

Toxicity: For Group B, grade 3-4 toxicities included anemia and dyspnea.

Results: For Group A (paclitaxel and carboplatin), the median overall survival was 14.5 months, compared to a survival of 11.1 months for Group B (mitoxantrone); this trend was not statistically significant. The authors concluded, "The results of the current Phase II interim analysis provide evidence that a 3-week regimen of pacliaxel-carboplatin induced a greater and more durable PSA response than mitoxantrone for HRPC treatment."

Support: Bristol Meyers Squibb supported this study. Bristol Meyers Squibb manufactures and/or markets paclitaxel and carboplatin.

Correspondence: Jacques-Olivier Bay

E-mail to a Friend Email Physician More Information